Skip to Content
  • It Costs More Than This

    Here’s another paper on the cost to develop a new drug, a topic about which, I’m convinced, debate will never end. This one is designed as a respons… Read More
  • Allergan Pulls A Fast One

    Friday brought news of a drug-company maneuver that I had never heard of, and didn’t even realize was possible. First, a bit of background; the stage need… Read More
  • Lilly Cuts Back, Again

    The Big Pharma story at the moment, sad to say, is that Eli Lilly is shedding a lot of employees: 3,500 or so (2000 of them in the US), about 8.5% of their glob… Read More
  • Good Craziness and Bad Craziness

    It’s fair to say that there’s a high level of excitement these days in biopharma (and the associated academic disciplines) due to the tools we have… Read More
  • GSK Rearranges, Once More

    There have been a lot of announcements in the biopharma field this week, and I’m just now getting around to GlaxoSmithKline’s from a couple of days… Read More
  • AstraZeneca Gets the Bad News

    After writing about Merck’s successes (so far) in immuno-oncology, it’s time to write about AstraZeneca’s failure. When the rumors started fly… Read More
  • Chaos at AstraZeneca

    What on earth is going on over at AstraZeneca? The company has had plenty of wild ups and downs over the years, and managed to fight off a takeover attempt by P… Read More
  • Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percenta… Read More
Page 2 of 10312345...102030...Last »